Hamill Laura
Insider CIK 1751804 · JAZZ Director · XLRN Director · ANAB Director · FATE Director · YMAB Director · SCLX Director · PRDS Director · GILD EVP, Worldwide Commercial Ops
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | F Tax w/h | 2026-08-31 | 2026-09-02 | 14 | $244.06 | $3.4K | 8,524 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | F Tax w/h | 2026-08-31 | 2026-09-02 | 1,692 | $241.39 | $408.4K | 6,832 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | F Tax w/h | 2026-08-31 | 2026-09-02 | 1,692 | $241.39 | $408.4K | 6,832 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | F Tax w/h | 2026-08-31 | 2026-09-02 | 14 | $244.06 | $3.4K | 8,524 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | A Award | 2026-08-05 | 2026-08-07 | 1,605 | — | $0 | 8,538 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | A Award | 2026-08-05 | 2026-08-07 | 1,605 | — | $0 | 8,538 | SEC↗ |
| FATE FATE THERAPEUTICS INC | A Award deriv | 2026-06-12 | 2026-06-15 | 175,800 | — | $0 | 175,800 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-19 | 16,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-19 | 14,545 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-19 | 13,950 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-19 | 33,450 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-19 | 11,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-19 | 27,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer | 2025-09-16 | 2025-09-19 | 25,080 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | U Tender | 2025-09-16 | 2025-09-19 | 5,825 | $8.60 | $50.1K | 0 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | F Tax w/h | 2025-08-08 | 2025-08-11 | 1,805 | $111.25 | $200.8K | 6,933 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | A Award | 2025-08-07 | 2025-08-11 | 3,507 | — | $0 | 8,738 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2025-06-30 | 2025-07-02 | 33,450 | — | $0 | 33,450 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award | 2025-06-30 | 2025-07-02 | 25,080 | — | $0 | 30,905 | SEC↗ |
| JAZZ Jazz Pharmaceuticals plc | A Award | 2024-08-02 | 2024-08-06 | 3,731 | — | $0 | 5,231 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2024-06-11 | 2024-06-13 | 14,545 | — | $0 | 14,545 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award | 2024-06-11 | 2024-06-13 | 3,495 | — | $0 | 5,825 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | D To issuer deriv | 2023-08-31 | 2023-08-31 | 37,500 | — | $0 | 0 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | D To issuer deriv | 2023-08-31 | 2023-08-31 | 75,000 | — | $0 | 0 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | D To issuer deriv | 2023-08-31 | 2023-08-31 | 37,500 | — | $0 | 0 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | D To issuer deriv | 2023-08-31 | 2023-08-31 | 70,390 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2023-06-08 | 2023-06-09 | 13,950 | — | $0 | 13,950 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award | 2023-06-08 | 2023-06-09 | 2,330 | — | $0 | 2,330 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | A Award deriv | 2023-06-01 | 2023-06-02 | 37,500 | — | $0 | 37,500 | SEC↗ |
| SCLX Scilex Holding Co | A Award deriv | 2023-01-17 | 2023-01-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2023-01-06 | 2023-01-10 | 3,900 | — | $0 | 3,900 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2023-01-06 | 2023-01-10 | 10,600 | — | $0 | 10,600 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2022-07-15 | 2022-07-19 | 16,000 | — | $0 | 16,000 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | A Award deriv | 2022-06-08 | 2022-06-10 | 37,500 | — | $0 | 37,500 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2022-02-10 | 2022-02-14 | 9,200 | — | $0 | 9,200 | SEC↗ |
| PRDS PARDES BIOSCIENCES, INC. | A Award deriv | 2021-12-23 | 2021-12-28 | 75,000 | — | $0 | 75,000 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 941 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 9,339 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | U Tender | 2021-11-19 | 2021-11-22 | 474 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2021-06-10 | 2021-06-14 | 16,000 | — | $0 | 16,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2021-02-10 | 2021-02-12 | 11,000 | — | $0 | 11,000 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award deriv | 2021-01-29 | 2021-02-02 | 941 | — | $0 | 941 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award | 2021-01-29 | 2021-02-02 | 474 | — | $0 | 474 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award deriv | 2020-09-15 | 2020-09-17 | 9,339 | — | $0 | 9,339 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2020-06-23 | 2020-06-24 | 32,000 | — | $0 | 32,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2020-02-12 | 2020-02-13 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2019-09-24 | 2019-09-26 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ANAB ANAPTYSBIO, INC | A Award deriv | 2019-09-24 | 2019-09-26 | 2,268 | — | $0 | 2,268 | SEC↗ |
| GILD GILEAD SCIENCES INC | A Award | 2019-05-08 | 2019-05-10 | 9,840 | — | $0 | 9,840 | SEC↗ |
| GILD GILEAD SCIENCES INC | F Tax w/h | 2019-05-08 | 2019-05-10 | 3,500 | $66.07 | $231.2K | 6,340 | SEC↗ |
| GILD GILEAD SCIENCES INC | A Award deriv | 2019-02-06 | 2019-02-08 | 63,100 | — | $0 | 63,100 | SEC↗ |
| GILD GILEAD SCIENCES INC | A Award deriv | 2019-02-06 | 2019-02-08 | 13,640 | — | $0 | 46,435 | SEC↗ |
| GILD GILEAD SCIENCES INC | A Award deriv | 2018-10-07 | 2018-10-09 | 87,680 | — | $0 | 87,680 | SEC↗ |
| GILD GILEAD SCIENCES INC | A Award deriv | 2018-10-07 | 2018-10-09 | 32,795 | — | $0 | 32,795 | SEC↗ |